A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra‐Long‐Acting β2‐Agonists Used for Asthma and COPD
Open Access
- 31 August 2025
- journal article
- research article
- Published by Wiley in Pharmacology Research & Perspectives
- Vol. 13 (5) , e70154
Abstract
β‐agonists have been used in asthma for 120 years. There are two recent changes: ultra‐long‐acting agonists for COPD and new asthma guidelines recommending formoterol/ICS inhalers phasing out short‐acting salbutamol inhalers. Few studies directly compare the molecular pharmacological properties of short (salbutamol, terbutaline, fenoterol), long (formoterol, salmeterol), and ultra‐long‐acting (indacaterol, olodaterol, vilanterol) β2‐agonists. Here, the in vitro molecular pharmacological properties of affinity, selectivity, intrinsic efficacy, and duration of β2‐agonists at human β2 and β1‐adrenoceptors and the 4 β2‐polymorphisms stably expressed in CHO cells were directly compared using radioligand binding and functional studies. Whilst short‐acting drugs were similar, there was huge variation and complete overlap in the molecular pharmacological properties of drugs labeled as long and ultra‐long‐acting β2‐agonists. Salmeterol and vilanterol were highly β2‐selective (> 1000‐fold) whereas indacaterol was similar to salbutamol (40‐fold). Formoterol and indacaterol were the most efficacious, whereas salmeterol had the longest duration of binding. Salmeterol and vilanterol utilize a β2‐specific exosite (β2‐H296‐K305) for high affinity and selectivity (that does not affect intrinsic efficacy or duration) whilst the β2‐selectivity of formoterol and olodaterol resides elsewhere. Duration of binding closely correlated with lipophilicity. β2‐polymorphisms had no substantial effect on β2‐agonist properties. Comparison with other β‐ligands suggests that affinity and duration could both be improved further. However, given the very wide range of molecular pharmacological properties of β‐agonists that are clinically effective and widely used, non‐pharmacological properties (physiochemical, patient factors, devices and combination inhaler availability) may be as important in final clinical patient outcomes as the molecular pharmacological properties of the individual β2‐agonists themselves.Keywords
All Related Versions
Funding Information
- Wellcome Trust (073377/Z/03/Z)
This publication has 53 references indexed in Scilit:
- Influence of β2-Adrenergic Receptor Genotypes on Signal Transduction in Human Airway Smooth Muscle CellsAmerican Journal of Respiratory Cell and Molecular Biology, 1995
- Relaxant effects and durations of action of formoterol and salmeterol on the isolated human bronchusEuropean Respiratory Journal, 1994
- Effects of β‐adrenoceptor agonists in human bronchial smooth muscleBritish Journal of Pharmacology, 1993
- Nebulized fenoterol causes greater cardiovascular and hypokalaemic effects than equivalent bronchodilator doses of salbutamol in asthmaticsRespiratory Medicine, 1992
- Salmeterol, a novel, long‐acting β2‐adrenoceptor agonist: characterization of pharmacological activityin vitroandin vivoBritish Journal of Pharmacology, 1991
- The Use of Adrenal Substance in the Treatment of AsthmaJournal of Asthma, 1990
- Cardiovascular and hypokalaemic effects of inhaled salbutamol, fenoterol, and isoprenaline.Thorax, 1989
- Evidence that the efficacy (intrinsic activity) of fenoterol is higher than that of salbutamol on β-adrenoceptors in guinea-pig tracheaEuropean Journal of Pharmacology, 1978
- Cardiorespiratory activitirs of 3-formylamino-4-hydroxy-alpha-(n-1-methyl-2-p-methoxyphenethylaminomethyl)-benzylalcohol-hemifumarate(BD 40A) and some other beta-adrenoceptor stimulants in conscious guinea pigs.1976
- α-[(t-Butylamino)methyl]-4-hydroxy-m-xylene-α1, α3-diol (AH.3365): a Selective β-Adrenergic StimulantNature, 1968